Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560934 | 0.79 | PTGER1 (0.52) | MEN1KMT2ACYP19A1HRH1FAAH | |
| SCHEMBL562080 | 0.77 | MEN1 (0.49) | ALDH1A1MEN1KMT2ACYP19A1HRH1 | |
| SCHEMBL696460 | 0.75 | CYP19A1 (0.45) | MEN1KMT2ACYP19A1HRH1FAAH | |
| SCHEMBL3440030 | 0.73 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACYP19A1L3MBTL1 | |
| SCHEMBL3440017 | 0.73 | KMT2A (0.66) | ALDH1A1MEN1KMT2AL3MBTL1TDP1 | |
| SCHEMBL560947 | 0.73 | KMT2A (0.51) | ALDH1A1MEN1KMT2ACYP19A1FAAH | |
| SCHEMBL634581 | 0.72 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ACYP19A1L3MBTL1 | |
| SCHEMBL16050517 | 0.72 | CYP19A1 (0.50) | CYP19A1HRH1FAAHMAOASLC6A4 | |
| SCHEMBL17137840 | 0.70 | FAAH (0.51) | MEN1KMT2ACYP19A1HRH1FAAH | |
| SCHEMBL19086755 | 0.70 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ACYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | ALDH1A1 1857/4885MEN1 2873/4885KMT2A 3401/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | ALDH1A1 447/4885MEN1 3849/4885KMT2A 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.